WO1993010114A1 - 3-pyridinol derivatives and their use as medicaments - Google Patents
3-pyridinol derivatives and their use as medicaments Download PDFInfo
- Publication number
- WO1993010114A1 WO1993010114A1 PCT/GB1992/002118 GB9202118W WO9310114A1 WO 1993010114 A1 WO1993010114 A1 WO 1993010114A1 GB 9202118 W GB9202118 W GB 9202118W WO 9310114 A1 WO9310114 A1 WO 9310114A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- group
- hereinbefore defined
- reacting
- Prior art date
Links
- 0 *c1cc(I)cnc1* Chemical compound *c1cc(I)cnc1* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Definitions
- the present invention relates to pyridinol derivatives, processes for their preparation, intermediates in their preparation, their use as medicaments and to pharmaceutical compositions comprising them.
- the compounds of this invention are agonists of a cyclic AMP-dependent protein kinase (cA-PrK) (see J. Biol. Chem., 1989, 264, 8443 - 8446) and are of use in combatting such
- cA-PrK cyclic AMP-dependent protein kinase
- agonism is thought to be beneficial. They are likely to have anti-proliferative, anti-aggregatory, cholesterol-lowering, smooth muscle relaxant, positive lusitropic, anti-allergic or anti-inflammatory activities. They are likely to be useful in the treatment of
- diastolic failure cancer, psoriasis, atheroschlerosis, thrombosis, re-stenosis, chronic reversible lung disease such as asthma and bronchitis, allergic disease such as allergic asthma, allergic rhinitis and urticaria or gut motility disorders such as irritable bowel syndrome.
- R 0 is OH or a bioprecursor thereof
- R 1 is A 0 CO 2 H, P(Z) (OH) (OR 2 ), SO 2 H, SO 3 H or 5-tetrazolyl or a bioprecursor thereof,
- a 0 is CH 2 , CHF, CF 2 , CR 3 (OR 4 ), CO or C(OR 5 ) (OR 6 ),
- R 2 is phenyl, C 3-5 cycloalkyl, C 3-5 cycloalkylC ⁇ _4alkyl, or C 1-8 alkyl optionally substituted by C 1-4 alkoxy,
- R 3 is H, methyl or ethyl,
- R 4 is H or C 1-3 alkyl
- R 5 and R 6 are each C 1-3 alkyl or together form a 1,2- ethanediyl group or 1,3-propanediyl group,
- Z is O or S
- Ar is phenyl optionally substituted by one to three groups independently selected from C 1-6 galkyl, C 2-6 -lkenyl, C 1-6 alkoxy, C 3-6 alkenyloxy, C 3-6 cycloalkyl,
- Ar is 1-naphthyl optionally substituted in the 4-position by hydroxy or C 1-6 alkoxy, 2-naphthyl optionally substituted in the 1-position by hydroxy or C 1-6 alkoxy,
- Bioprecursors of the groups R 0 and R 1 are derivatives thereof which are convertible in vivo into the groups R 0 and R 1 .
- a suitable bioprecursor of the group R 0 is OR 8 wherein R 8 is C 1-4 alkanoyl (for example acetyl), arylC 1-4 alkanoyl (for example phenyl C 1-4 alkanoyl such as benzoyl), arylsulphonyl (for example optionally substituted phenylsulphonyl or
- toluenesulphonyl or C 1-4 alkylsulphonyl (for example methylsulphonyl) .
- a suitable bioprecursor is A 0 CO 2 R 9 wherein R 9 is an ester-forming group.
- Suitable O-protecting groups include pivaloyloxymethyl, propionyloxymethyl and pivalolyloxycarbonyloxymethyl.
- R 1 is 5-tetrazolyl
- a suitable bioprecursor is an
- N-protected derivative thereof include pivalolyloxymethyl, propionyloxymethyl and
- bioprecursors of the groups R 0 and R 1 are those formed when R 1 and R 0 are linked together to form a cyclic structure such that R 1 -R 0 is A 1 C0 2 or A 2 OCH 2 O, in which :
- a 1 is CH 2 , CHF, CF 2 , CR 3 (OR 4 ), CO or C(OR 5 ) (OR 6 ),
- a 2 is P(Z)OR 2 or CR 3 (CO 2 R 9 ), and R 2 to R 6 , R 9 and Z are as hereinbefore defined.
- R 0 is hydroxy or OR 8 , preferably hydroxy.
- R 1 is A 0 CO 2 H or A 0 CO 2 R 9 .
- R 1 is P(Z) (OH) (OR 2 ) or P(Z) (OR 2 ) 2 .
- R 1 is SO 2 H, SO 3 H or 5-tetrazolyl.
- R 1 and R 0 are linked together such that R 1 -R 0 0s A 1 CO 2 .
- R 1 and R 0 are linked together such that R 1 -R 0 is A 2 OCH 2 O.
- alkyl is meant both straight- and branched- chain alkyl.
- C 1-6 polyfluoroalkyl is meant a C 1-6 alkyl group having at least one hydrogen replaced with fluoro, e.g. CF 3 or CF 2 CF 2 H.
- R 2 is methyl, ethyl, propyl, butyl, pentyl, hexyl, 2-methoxyethyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclopropylmethyl.
- R 3 is H, methyl or ethyl, preferably H or methyl.
- R 4 is H, methyl, ethyl or propyl, preferably H or methyl.
- R 5 and R 6 are independently methyl, ethyl or propyl, preferably together they form a 1,2-ethanediyl group.
- Z is 0.
- R 9 is C 1-4 alkyl optionally substituted by hydroxy, e.g. 2-hydroxyethyl or arylC 1-4 alkyl (for example
- phenylC 1-4 alkyl such as benzyl
- Ar is phenyl optionally mono-substituted by a group as hereinbefore defined, for example in the 2,3, or 4
- Ar is phenyl di-substituted by any groups as
- Ar is phenyl trisubstituted by any groups as hereinbefore defined, for example in the 2,3,4-, 2,3,5-, or 3,4,5-positions by groups independently selected from
- Ar is 1-na ⁇ hthyl optionally substituted in the 4-position by hydroxy or C ⁇ -galkoxy.
- Ar is
- 2-naphthyl optionally substituted in the 1-position by hydroxy or C 1-6 alkoxy.
- Ar is 3-phenanthryl or 9-phenanthryl.
- Ar is 2-quinolinyl or 4-quinolinyl.
- Ar is 2-benzofuranyl or 3-thianaphthenyl.
- C 1-6 alkoxy examples include methoxy, ethoxy, propoxy, butoxy, or pentyloxy.
- Examples of C 1-6 alkyl include methyl, ethyl, propyl, butyl, isobutyl or pentyl.
- halo examples include fluoro, chloro, bromo or iodo.
- Particular compounds of this invention include : ethyl [5-(2-naphthyl)-3-hydroxy-2-pyridyl]phosphonate, 5-(2,4-dipropoxyphenyl)-2-(5-tetrazolyl)pyridin-3-ol, or
- Compounds of the formula (1) can form pharmaceutically acceptable base addition salts with metal ions, such as alkali metals for example sodium or potassium, or with an ammonium ion.
- metal ions such as alkali metals for example sodium or potassium, or with an ammonium ion.
- acceptable salts may be administered in standard manner for the treatment of the indicated diseases, for example orally, sublingually, parenterally, transdermally, rectally, via inhalation or via buccal administration.
- an oral liquid formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent.
- a liquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent.
- any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include starch, celluloses, lactose, sucrose and magnesium stearate.
- any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell.
- any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be
- aqueous gums celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell.
- Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous
- non-aqueous carrier optionally containing a parenterally acceptable oil or solubilising agent, for example
- polyethylene glycol polyvinylpyrrolidone, lecithin,
- a typical suppository formulation comprises a compound of formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogues.
- a binding and/or lubricating agent for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogues.
- Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream,
- ointment lotion or paste or are in the form of a medicated plaster, patch or membrane.
- compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane, or are in the form of a powder for insufflation.
- a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane
- the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a single dose.
- Each dosage unit for oral administration contains suitably from 0.001 mg/Kg to 30 mg/Kg, and preferably from 0.005 mg/Kg to 15 mg/Kg, and each dosage unit for parenteral
- administration contains suitably from 0.001 mg/Kg to 10 mg/Kg, of a compound of formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid.
- the daily dosage regimen for oral administration is suitably about 0.001 mg/Kg to 120 mg/Kg, of a compound of formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid.
- the daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, for example about 0.005 mg/Kg to 10 mg/Kg, of a compound of the formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid.
- the active ingredient may be administered as required for example from 1 - 8 times a day or by infusion.
- the compositions of the invention are agonists of a cA-PrK and are of use in combatting such conditions where such agonism is thought to be beneficial. Such conditions can be treated by administration orally, sublingually topically, rectally, parenterally or by
- inhalation For administration by inhalation dosages are controlled by a valve, are administered as required and for an adult are conveniently in the range 0.1 - 5.0 mg of a compound of the formula (1) or a pharmaceutically acceptable salt thereof.
- the compounds of this invention may be co-administered with other pharmaceutically active compounds, for example in combination, concurrently or sequentially. Conveniently the compounds of this invention and the other active compound or compounds are formulated in a single pharmaceutical
- bronchodilators such as sympathomimetic amines for example isoprenaline, isoetharine, sulbutamol, phenylephrine and ephedrine or xanthine derivatives for example
- anti-allergic agents for example disodium cromoglycate, histamine H 1 -antagonists
- drugs used in the treatment of cancer such as those which inhibit the synthesis of or inactivate DNA, for example methotrexate, fluoracil, cisplatin, actinomycin D, anti- atherschlerotic agents for example cholesterol lowering drugs such as HMGCoA reductase inhibitors, bile acid sequestrants, drugs for the treatment of psoriasis, for example retinoids, anthralin, anti-inflammatories for example cortiscosteroids, non-steroid anti-inflammatories such as aspirin,
- antithrombotics for example dipyridamole, or fibrinolytic agents.
- the present invention provides a process for the preparation of compounds of the formula (1) or pharmaceutically acceptable salts thereof, which process comprises : a) for compounds wherein R 1 is A 0 CO 2 H or A 0 CO 2 R 9 and : i) A 0 is CR 3 (OR 4 ),
- R 11 is an O-protecting group and Ar is as
- R 12 is CR 3 (OH)CO 2 R 9 and R 3 , R 9 , R 11 , and Ar are as hereinbefore defined and thereafter optionally reacting with a C 1-3 alkylating agent to form the corresponding compound wherein R 12 is CR 3 (OC 1-3 alkyl) CO 2 R 9 , ii) A 0 is CO,
- R 9 O 2 CCO 2 R 9 (5) wherein R 9 is as hereinbefore defined to form a compound of the formula (4) wherein R 12 is COCO2R 9 and R 9 , R 11 and Ar are as hereinbefore defined, iii) A 0 is CH(OH),
- R 12 is CH(OH)CO 2 R 9 and R 9 , R 11 , and Ar are as hereinbefore defined with a fluorinating agent to form the corresponding compound wherein R 12 is CHFCO2R 9 , and thereafter optionally : o converting the group OR 11 into OH o converting the group A 0 CO 2 R 9 into A 0 CO 2 H; or b) for compounds wherein R 1 is CH 2 CO 2 H,
- R 13 is acetyl and Ar is as hereinbefore defined into the corresponding compound wherein R 13 is CH 2 CO 2 H; or c) for compounds wherein R 1 is CH(OR 4 )CO 2 H reacting a compound of the formula (4) wherein R 12 is -CH(OH)CN with a C 1-3 alkylating agent and/or converting the group CN into CO 2 H, and optionally converting the group OR 11 into OH; or d) for compounds wherein R 1 is P (O) (OH) (OR 2 ),
- R 13 is P (O) (OR 2 ) 2 and R 2 , and Ar are as hereinbefore defined; or e) for compounds wherein R 1 is P(S) (OH) (OR 2 ), converting a compound of the formula (6) wherein R 13 is P (O) (NHR 14 ) (OR 2 ) and R 14 is phenyl or C 1-4 alkyl and Ar is as hereinbefore defined into the corresponding compound wherein R 13 is
- R b is a group R 1 as hereinbefore defined or a
- R a is a group R 0 as hereinbefore defined or a precursor thereof and L is a leaving group with a compound of the formula (8):
- a compound of the formula (2) is reacted with a strong base such as lithium diisopropylamide, or a C 1 - 4 alkyl lithium or aryl lithium such as mesityl lithium in an organic solvent such as tetrahydrofuran, diethylether or
- the strong base may be formed in situ, for example by the addition of a C 1-4 alkyl lithium e.g. methyllithium followed by a catalytic quantity of diisopropylamine.
- a suitable compound of the formula (3) is ethylpyruvate, or ethyl glyoxylate or a chemical equivalent thereof and a suitable compound of the formula (5) is diethyloxalate.
- a compound of the formula (4) wherein R 12 is CR 3 (OH)CO 2 R 9 is suitably reacted with a C ⁇ _3alkylating agent such as
- iodomethane, iodopropane or dimethylsulphate in the presence of a base such as sodium hydride or potassium hydroxide in an organic solvent such as dimethylformamide or
- dimethylsulphoxide at elevated (e.g. 30 - 80°C) or preferably ambient temperature to form the corresponding compound
- R 12 is CR 3 (OC 1-3 alkyl) CO 2 R 9 .
- a compound of the formula (4) wherein R 12 is COCO 2 R 9 is suitably reacted with a reducing agent such as sodium borohydride, or diisobutylaluminium hydride in an organic solvent such as dichloromethane, a C 1-4 alcohol e.g. ethanol, or acetic acid or mixtures thereof at ambient or elevated temperature (e.g. 30 - 80°C), or with cooling (e.g. 0 - 5°C) to form the corresponding compound wherein R 12 is
- COCO 2 R 9 is suitably reacted with a reducing agent such as a zinc amalgam in hydrochloric acid in the absence of a solvent or in a solvent such as ethanol, acetic acid or dioxan and hydrogen chloride gas at ambient or elevated temperature (e.g. 40-100°C) to form the corresponding compound wherein R 12 is CH 2 CO 2 H. Under these reaction conditions the CO 2 R 9 group is converted to carboxy.
- a reducing agent such as a zinc amalgam in hydrochloric acid in the absence of a solvent or in a solvent such as ethanol, acetic acid or dioxan and hydrogen chloride gas at ambient or elevated temperature (e.g. 40-100°C)
- a compound of the formula (4) wherein R 12 is COCO 2 R 9 is suitably reacted with a C 1-3 alcohol, 1,2-ethanediol or 1,3- propanediol in the presence of an acid catalyst such as paratoluenesulphonic acid, concentrated sulphuric acid or anhydrous hydrogen chloride, at ambient or elevated
- CHOHCO 2 R 9 is suitably reacted with a fluorinating agent such as diethylaminosulphur trifluoride in an organic solvent such as a halohydrocarbon or an ether such as glyme, or THF at ambient or elevated temperature (e.g. 30-60°C) to form the corresponding compound where R 12 is CF 2 CO 2 R 9 or CHFCO 2 R 9 respectively.
- a fluorinating agent such as diethylaminosulphur trifluoride
- organic solvent such as a halohydrocarbon or an ether such as glyme, or THF
- O-protecting groups for R 11 include methyl or benzyl.
- OR 11 is hydroxy by reaction with sodium iodide and chlorotrimethylsilane in an organic solvent such as acetonitrile, or a halohydrocarbon e.g. dichloromethane or chloroform at elevated (e.g. 30 - 80°C) or preferably ambient temperature.
- an organic solvent such as acetonitrile, or a halohydrocarbon e.g. dichloromethane or chloroform at elevated (e.g. 30 - 80°C) or preferably ambient temperature.
- This method is particularly suitable for preparing compounds of the formula (1) wherein R 1 is A 0 CO 2 R 9 since the ester-forming group R 9 is not hydrolysed under the reaction conditions.
- Another method utilises sodium
- a compound of the formula (4) wherein R 12 is A 0 CO 2 R 9 can suitably be converted to the corresponding compound wherein R 12 is A 0 CO 2 H by reaction with an aqueous base such as sodium or potassium hydroxide at ambient or elevated temperature
- This method is particularly suitable for preparing compounds of the formula (1) wherein R 0 is methoxy since the OR 11 group is not hydrolysed.
- Another hydrolysis method utilises aqueous acid such as concentrated
- hydrochloric acid at an elevated temperature e.g. 40 ⁇
- hydrolysis with an aqueous base such as sodium hydroxide at elevated temperature, preferably at the reflux temperature of the reaction mixture.
- aqueous base such as sodium hydroxide
- a compound of formula (4) where R 12 is -CH(OH)CN is reacted with a C 1-3 alkylating agent as hereinbefore described followed by reaction with aqueous mineral acid such as hydrochloric acid at ambient or elevated temperature, preferably at reflux in order to prepare the corresponding compound where R 12 is CH(OC 1-3 alkyl) CO 2 H.
- aqueous mineral acid such as hydrochloric acid
- the alkylation can be omitted if the corresponding compound where R 12 is CH(OH)CO 2 H is desired.
- the OR 11 group may be converted to hydroxy. If not and if desired this group can be converted to hydroxy as
- a compound of the formula (4) wherein R 12 is -CH(OH)CN can be prepared by reacting the corresponding compound wherein R 12 is -CHO with a source of cyanide such as potassium cyanide in the presence of acid such as hydrochloric acid, preferably at ambient temperature.
- a compound of the formula (4) or (6) where R 12 or R 13 is CHO is suitably prepared by reacting the corresponding compound wherein R 12 or R 13 is cyano with a suitable reducing agent such as diisobutylaluminium hydride followed by aqueous acidic work-up.
- a suitable reducing agent such as diisobutylaluminium hydride followed by aqueous acidic work-up.
- P(O) (OR 2 ) 2 is hydrolysed by reaction with an aqueous base such as sodium hydroxide optionally in a cosolvent such as a C 1-4 alcohol at an elevated temperature (e.g. 40-100°C), preferably at the reflux temperature of the reaction mixture.
- an aqueous base such as sodium hydroxide
- a cosolvent such as a C 1-4 alcohol
- a compound of the formula (4) wherein R 12 is cyano or a compound of the formula (6) wherein R 13 is cyano is suitably reacted with an azide salt such as ammonium, sodium or aluminium azide in an organic solvent such as dimethylformamide, dimethylsulphoxide, N-methylpyrrolidone or
- tetrahydrofuran at an elevated temperature e.g. 40-200°C, preferably at 100-150°C to form the corresponding
- a compound of the formula (7) is reacted with a compound of the formula (8) in the presence of 1-50 mole %, preferably 2-10 mole %, of a palladium catalyst and a base such as triethylamine, sodium bicarbonate, or aqueous sodium carbonate and optionally lithium chloride in an organic solvent such as dimethylformamide, dimethoxyethane,
- L 1 is halo for example iodo, bromo or chloro, preferably L 1 is a trifluoromethanesulphonate.
- palladium catalysts that can be used include: tetrakis(triphenylphosphine)palladium (Pd[PPh 3 ] 4 ),
- a chemical equivalent of a compound of the formula (8) is meant a reagent that can couple the Ar group onto the pyridyl ring of a compound of the formula (7).
- aryl stannanes can be used, such as ArSnMe3 which can suitably be prepared by reacting a suitable aryl halide (such as ArBr or Arl) with a base such as t-butyl lithium followed by reaction with a trimethyl tin halide (e.g. Me 3 SnCl).
- a suitable aryl halide such as ArBr or Arl
- a base such as t-butyl lithium
- a trimethyl tin halide e.g. Me 3 SnCl
- the aryl halide can be reacted with Me3SnSnMe3 in the
- R a is a group R 0 as hereinbefore defined and R b is a group R 1 as hereinbefore defined
- reaction of a compound of the formula (7) with a compound of the formula (8) results directly in compounds of the formula (1).
- An example of a precursor for R 1 is when R b is hydrogen.
- R 0 examples of a precursor for R 0 is when R a is halo, such as chloro, which can be converted to another precursor OR 11 , such as methoxy or benzyloxy by reaction with either sodium methoxide or benzyl alcohol and a base such as potassium tert butoxide preferably in the presence of a crown ether such as 18-crown-6 or 15-crown-5.
- R a is chloro
- R b is hydrogen and L 1 is trifluoromethane sulphonate
- R a is chloro
- R b is hydrogen and L 1 is trifluoromethane sulphonate
- Such a compound can then be converted into a compound of the formula (1) as herein
- R 1 include CN, CHO or COMe.
- Reaction of a compound of the formula (7) wherein R b represents such a precursor and R a is OH or OR 11 with a compound of the formula (8) or a chemical equivalent thereof results in a compound of the formula (4) or a compound of the formula (6) wherein R 12 or R 13 is CN, CHO or COMe.
- Such compounds can be converted to compounds of the formula (1) as herein described.
- a compound of the formula (1) wherein R 1 is A 0 CO 2 can be converted to the corresponding compound wherein R 1 is A 0 CO 2 R 9 by reaction with a compound R 9 OH wherein R 9 is as hereinbefore defined.
- a compound of the formula (1) wherein R ⁇ is OH can be converted to the corresponding compound where R ⁇ is OR ⁇ by reaction with R 8 L 2 wherein R 8 is as hereinbefore defined an L 2 is a leaving group such as halo e.g. bromo, chloro, iodo.
- P (Z) (OR 2 ) (OH) can be converted to the corresponding compound wherein R 1 is P(Z) (OR 2 ) (OR 10 ) by reaction with a suitable O-protecting agent in standard manner.
- a suitable O-protecting agent for example the compound can be reacted with a pivalolyloxymethyl halide.
- a compound of the formula (1) wherein R 1 is 5-tetrazole can be reacted with a suitable N-protecting agent in standard manner, for example with a pivalolyloxymethyl halide.
- a compound of the formula (1) wherein R 1 -R 0 is A 1 C O2 is suitably prepared by heating a compound of the formula (1) wherein R 1 is A 1 CO 2 H and R 0 is OH with a dehydrating agent such as acetic anhydride, at an elevated temperature (e.g. 40 - 200°C), preferably at the reflux temperature of the
- a compound of the formula (1) wherein R 1 -R 0 is A 2 OCH 2 O is suitably prepared by reacting a compound of the formula (1) wherein R 1 is A 2 OH and R 0 is OH with a dihalomethane such as diiodo- or dibromomethane in the presence of silver carbonate in an organic solvent such as dimethylformamide at an
- elevated temperature e.g. 40 - 120°C.
- a compound of the formula (2) is suitably prepared by
- dimethylformamide dimethylacetal in dimethylformamide or trimethylphosphite at an elevated temperature e.g. 40 - 120°C
- iodomethane and silver carbonate in toluene or chloroform e.g. 40 - 120°C
- an O-benzylating agent such as benzyl bromide or chloride in the presence of a base
- a compound of the formula (6) wherein R 13 is acetyl can also be prepared by reacting a compound of the formula (6) wherein R 13 is cyano with methyl lithium followed by aqueous acidic work up with for example hydrochloric acid.
- a compound of the formula (6) wherein R 13 is hydrogen can be prepared by reacting a compound of the formula (6) wherein R 13 is cyano with orthophosphoric acid at an elevated
- a compound of the formula (6) wherein R 13 is cyano or acetyl and Ar is as hereinbefore defined can be suitably prepared by reaction of a compound of formula (4) wherein R 12 is cyano or acetyl and R 11 and Ar are as hereinbefore defined with a demethylating agent or debenzylating agent as hereinbefore described.
- a compound of formula (4) wherein R 12 is cyano is suitably prepared by reacting the anion of a compound of formula (2) wherein Ar and R 11 are as hereinbefore defined with
- a compound of the formula (4) where R 12 is cyano is more suitably prepared by reacting a compound of the formula (9)
- Ar and R 11 are as hereinbefore defined with a dimethyl carbamoyl halide such as the chloride folowed by reaction with trimethylsilylcyanide, conveniently at ambient temperature in a solvent such as dichloromethane.
- a dimethyl carbamoyl halide such as the chloride folowed by reaction with trimethylsilylcyanide, conveniently at ambient temperature in a solvent such as dichloromethane.
- a compound of the formula (9) is suitably prepared by reacting a compound of the formula (2) with an oxidising agent such as metachloroperbenzoic acid in an organic solvent such as dichloromethane.
- a compound of the formula (6) wherein R 13 is P (O) (OR 2 ) 2 can be prepared by treating a compound of the formula (2) wherein RH is P (O) (OR 2 ) 2 with a strong base such as lithium
- a compound of the formula (2) wherein R 11 is P (O) (OR 2 ) 2 is suitably prepared by treating a compound of the formula (6) wherein R 13 is hydrogen with a compound of the formula (10):
- L 3 is halo, for example chloro or bromo.
- a compound of formula (2) wherein R 11 is P (O) (OR 2 ) 2 can also be prepared by treating a compound of the formula (6) wherein R 13 is hydrogen with a compound of the formula (11): HP(O) (OR 2 ) 2 (11) wherein R 2 is as hereinbefore defined in the presence of an amine base such as triethylamine, and carbon tetrachloride.
- a compound of the formula (6) wherein R 13 is P (O) (OR 2 ) 2 is suitably prepared by treating a compound of the formula (6) wherein R 13 is hydrogen with a compound of the formula (10) in the presence of a strong base such as lithium diisopropylamide in an organic solvent such as
- a compound of formula (6) wherein R 13 is hydrogen is suitably prepared by demethylating or debenzylating a compound of formula (2) as hereinbefore defined.
- a compound of formula (2) wherein OR 11 is methoxy is treated with boron tribromide in an organic solvent such as dichloromethane or toluene with cooling (e.g. -80 to 10°C) followed by ambient temperature and aqueous work-up.
- a compound of formula (2) is treated with sodium iodide and chlorotrimethylsilane at ambient or elevated temperature (e.g. 40-80°C)
- a compound of the formula (6) wherein R 13 is P (O) (NHR 14 ) (OR 2 ) can be prepared by reaction of a compound of the formula (6) wherein R 13 is P (O) (OH) (OR 2 ) with carbon tetrachloride, triphenylphosphine and aniline or a C ⁇ _4alkylamine in an organic solvent such as pyridine at ambient temperature or with cooling (e.g. -10 to 5°C).
- a compound of the formula (6) where R 13 is P (O) (OH) (OR 2 ) can be reacted with dimethylformamide and oxalyl chloride in an organic solvent such as a halo hydrocarbon e.g. dichloromethane at ambient temperature, followed by reaction with aniline or a C 1-4 alkylamine preferably with cooling (-10 to 5°C).
- R a and L 1 are as hereinbefore defined using similar methods to those described for preparing compounds of the formula (1).
- a compound of the formula (7) wherein R b is P (O) (OR 2 ) 2 can be prepared by reacting a compound of the formula (12) wherein R a is OH with a compound of the formula (10) or (11) in similar manner to the reaction of a compound of the formula (6) wherein R 13 is hydrogen with a compound of the formula (10) or (11). If desired the group R a can then be converted to OR 11 as hereinbefore described.
- a compound of the formula (12) where R a is OR 11 can be treated in the presence of a strong base with a compound of the formula (3), a compound of the formula (5), sulphuryl chloride, sulphur dioxide or dimethylformamide to prepare a compound of the formula (7) wherein PP is
- CR 3 (OR 4 )CO 2 R 9 COCO 2 R 9 , SO 3 H, SO 2 H or CHO respectively in similar manner to the corresponding reaction with a compound of the formula (2) as hereinbefore described.
- Particularly suitable as a strong base is lithium tetramethyl piperidide.
- a compound of the formula (12) wherein R a is chloro and L 1 is trifluoromethanesulphonate is suitably prepared by reacting 3-chloro-5-hydroxy pyridine with trifluoromethane sulphonic anhydride in the presence of a suitable base, e.g. 4-N,N- dimethylaminopyridine in an organic solvent such as
- a compound of the formula (8) is suitably prepared by
- Ar-L 4 (13) wherein L 4 is bromo or iodo and Ar is as hereinbefore defined with a tri-C 1-4 alkylborate such as trimethyl, tri-isopropyl or tri-n-butyl borate in an organic solvent such as diethyl ether or tetrahydrofuran with cooling (e.g. - 80-10°C).
- a tri-C 1-4 alkylborate such as trimethyl, tri-isopropyl or tri-n-butyl borate in an organic solvent such as diethyl ether or tetrahydrofuran with cooling (e.g. - 80-10°C).
- a bromo group may be introduced into a suitably substituted phenyl ring (eg. disubstituted in the 2- and 4-positions by electron-donating groups such as
- a suitable nitrating agent such as nitronium tetrafluoroborate.
- a suitable nitrating agent such as nitronium tetrafluoroborate.
- Such a group can be readily hydrogenated to an amino group which if desired can be converted to a NHCOR 7 group by reaction with LCOR 7 wherein L is a leaving group and R 7 is as hereinbefore defined.
- Suitable examples of the reagent LCOR include acid halides (L is halo eg. chloro or bromo) or acid anhydrides (L is OCOR 7 ).
- Suitable functionalisations include the introduction of an allyl group ortho to a hydroxy substituent on a phenyl ring by reaction with an allyl halide, eg. bromide, to form an allyloxy derivative which on heating undergoes a Claisen rearrangement to form an ortho allyl hydroxy derivative.
- the hydroxy group can in turn be functionalised, eg. by reaction with a C 1-6 alkyl halide to form a C 1-6 alkoxy group.
- an allyl group can be converted to an E-1-propenyl group by reaction with a strong base, such as sodium
- An E-1-propenyl group can be cleaved to a formyl group by reaction with an oxidising agent such as
- N-methylmorpholine-N-oxide in the presence of a catalyst suc as osmium tetroxide to form a 1,2,dihydroxypropyl group whic on reaction with an oxidising agent such as sodium periodate forms the formyl group.
- a catalyst suc as osmium tetroxide suc as osmium tetroxide to form a 1,2,dihydroxypropyl group whic on reaction with an oxidising agent such as sodium periodate forms the formyl group.
- an oxidising agent such as sodium periodate
- the E-1-propenyl grou can be converted directly to a formyl group by reaction with a mixture of osmium tetroxide and sodium periodate or by reaction with ozone.
- a formyl group can in turn be further functionalised, for example it can be converted to a
- hydroxymethyl group by reaction with a suitable reducing agent such as sodium borohydride, the hydroxymethyl group then being reacted further, eg. with a C 1-6 alkyl halide to form a C 1-6 alkoxymethyl group.
- R 7 is as hereinbefore defined.
- Pharmaceutically acceptable base addition salts of the compounds of the formula (1) may be prepared by standard methods, for example by reacting a solution of the compound of the formula (1) with a solution of the base.
- Type II cA-PrK was prepared from the cardiac muscle of a cow. The supernatant from a muscle homogenate (3 mis of 10 mM potassium phosphate, 1 mM EDTA per g tissue) was applied to a column of DEAE-cellulose equilibrated with the homogenisation buffer and the type II cA-PrK was eluted with homogenisation buffer containing 350 mM sodium chloride (Rannels et al., 1983, Methods Enzymol., 99, 55-62). Type II cA-PrK was assayed for phosphotransferase activity by incubating the enzyme at 30°C for 5 minutes with
- substrate such as malantide (Malencik et al., 1983, Anal.
- phosphocellulose papers The concentration of compound required to give 10% phosphotransferase activation is given as the EC 10 ( ⁇ M).
- the compounds of Examples 1 to 3 had EC 10 values in the range 1.8 to 100 ⁇ M.
- Human platelet-rich-plasma was separated from freshly drawn blood (in acid/citrate/dextrose) and treated with 100 ⁇ M acetylsalicylic acid for 15 minutes at 37°C.
- a washed platelet suspension was then prepared in a Hepes-isotonic saline buffer after a single centrifugation step and adjusted to a concentration of 1.5 ⁇ 10 8 cells/ml. Aliquots of this suspension were pre-incubated with compounds for 5 minutes at 37°C, then challenged with 1.0 ⁇ M U46619. The extent of aggregation after 2 minutes were expressed as a percentage of control and results obtained are expressed as an IC 50
- the compound of Example 1 had a IC 50 value of 100 ⁇ M.
- Papillary muscles from the right ventricle of female Albino New Zealand rabbits are mounted in standard organ baths containing oxygenated Krebs solution.
- One end of the muscle is connected to an isometric transducer which allowed
- compositions for oral administration are prepared by combining the following :
- the formulations are then filled into individual soft gelatin capsules.
- a pharmaceutical composition for parenteral administration is prepared by dissolving the title compound of Example 2
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5509094A JPH07501070A (en) | 1991-11-20 | 1992-11-16 | 3-Pyridinol derivatives and their pharmaceutical uses |
EP92923524A EP0613476A1 (en) | 1991-11-20 | 1992-11-16 | 3-pyridinol derivatives and their use as medicaments |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919124578A GB9124578D0 (en) | 1991-11-20 | 1991-11-20 | Chemical compounds |
GB9124578.7 | 1991-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993010114A1 true WO1993010114A1 (en) | 1993-05-27 |
Family
ID=10704881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1992/002118 WO1993010114A1 (en) | 1991-11-20 | 1992-11-16 | 3-pyridinol derivatives and their use as medicaments |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0613476A1 (en) |
JP (1) | JPH07501070A (en) |
AU (1) | AU2930392A (en) |
CA (1) | CA2124002A1 (en) |
GB (1) | GB9124578D0 (en) |
MX (1) | MX9206710A (en) |
NZ (1) | NZ245167A (en) |
PT (1) | PT101072A (en) |
TW (1) | TW221990B (en) |
WO (1) | WO1993010114A1 (en) |
ZA (1) | ZA928893B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003051366A2 (en) | 2001-12-13 | 2003-06-26 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
US6770661B2 (en) | 2001-09-07 | 2004-08-03 | Euro-Celtique S.A. | Aryl substituted pyridines and their use |
US7105549B2 (en) | 2001-09-07 | 2006-09-12 | Euro-Celtique S.A. | Aryl substituted pyridines and the use thereof |
US7186749B2 (en) | 2004-08-23 | 2007-03-06 | Wyeth | Pyrrolo-naphthyl acids and methods for using them |
US20090221591A1 (en) * | 2005-03-03 | 2009-09-03 | Universitat Des Saarlandes | Selective Inhibitors of Human Corticosteroid Synthases |
US7605172B2 (en) | 2004-08-23 | 2009-10-20 | Wyeth | Thiazolo-naphthyl acids |
US7754747B2 (en) | 2004-08-23 | 2010-07-13 | Wyeth Llc | Oxazolo-naphthyl acids |
WO2023240253A3 (en) * | 2022-06-10 | 2024-02-08 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0428268A2 (en) * | 1989-10-13 | 1991-05-22 | Smith Kline & French Laboratories Limited | Pharmaceutical phenylpyridone derivatives |
WO1991017987A1 (en) * | 1990-05-21 | 1991-11-28 | Smith Kline & French Laboratories Limited | Phenol and pyridinol derivatives as pharmaceuticals |
WO1992006085A1 (en) * | 1990-09-28 | 1992-04-16 | Smith Kline & French Laboratories Limited | Phenylpyridinol derivatives as medicaments |
-
1991
- 1991-11-20 GB GB919124578A patent/GB9124578D0/en active Pending
-
1992
- 1992-11-16 CA CA002124002A patent/CA2124002A1/en not_active Abandoned
- 1992-11-16 AU AU29303/92A patent/AU2930392A/en not_active Abandoned
- 1992-11-16 JP JP5509094A patent/JPH07501070A/en active Pending
- 1992-11-16 EP EP92923524A patent/EP0613476A1/en not_active Withdrawn
- 1992-11-16 WO PCT/GB1992/002118 patent/WO1993010114A1/en not_active Application Discontinuation
- 1992-11-18 PT PT101072A patent/PT101072A/en not_active Application Discontinuation
- 1992-11-18 ZA ZA928893A patent/ZA928893B/en unknown
- 1992-11-18 NZ NZ245167A patent/NZ245167A/en unknown
- 1992-11-19 MX MX9206710A patent/MX9206710A/en unknown
- 1992-11-19 TW TW081109270A patent/TW221990B/zh active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0428268A2 (en) * | 1989-10-13 | 1991-05-22 | Smith Kline & French Laboratories Limited | Pharmaceutical phenylpyridone derivatives |
WO1991017987A1 (en) * | 1990-05-21 | 1991-11-28 | Smith Kline & French Laboratories Limited | Phenol and pyridinol derivatives as pharmaceuticals |
WO1992006085A1 (en) * | 1990-09-28 | 1992-04-16 | Smith Kline & French Laboratories Limited | Phenylpyridinol derivatives as medicaments |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105549B2 (en) | 2001-09-07 | 2006-09-12 | Euro-Celtique S.A. | Aryl substituted pyridines and the use thereof |
US7943643B2 (en) | 2001-09-07 | 2011-05-17 | Purdue Pharma L.P. | Aryl substituted pyridines and the use thereof |
US6770661B2 (en) | 2001-09-07 | 2004-08-03 | Euro-Celtique S.A. | Aryl substituted pyridines and their use |
US7579367B2 (en) | 2001-09-07 | 2009-08-25 | Purdue Pharma L.P. | Aryl substituted pyridines and the use thereof |
US6831175B2 (en) | 2001-12-13 | 2004-12-14 | Abbott Laboratories | Kinase inhibitors |
WO2003051366A2 (en) | 2001-12-13 | 2003-06-26 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
WO2003051366A3 (en) * | 2001-12-13 | 2004-03-25 | Abbott Lab | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
US7186749B2 (en) | 2004-08-23 | 2007-03-06 | Wyeth | Pyrrolo-naphthyl acids and methods for using them |
US7605172B2 (en) | 2004-08-23 | 2009-10-20 | Wyeth | Thiazolo-naphthyl acids |
US7754747B2 (en) | 2004-08-23 | 2010-07-13 | Wyeth Llc | Oxazolo-naphthyl acids |
US20090221591A1 (en) * | 2005-03-03 | 2009-09-03 | Universitat Des Saarlandes | Selective Inhibitors of Human Corticosteroid Synthases |
US9271963B2 (en) * | 2005-03-03 | 2016-03-01 | Universitat Des Saarlandes | Selective inhibitors of human corticosteroid synthases |
WO2023240253A3 (en) * | 2022-06-10 | 2024-02-08 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
Also Published As
Publication number | Publication date |
---|---|
TW221990B (en) | 1994-04-01 |
GB9124578D0 (en) | 1992-01-08 |
AU2930392A (en) | 1993-06-15 |
ZA928893B (en) | 1994-05-18 |
CA2124002A1 (en) | 1993-05-27 |
JPH07501070A (en) | 1995-02-02 |
PT101072A (en) | 1994-02-28 |
EP0613476A1 (en) | 1994-09-07 |
MX9206710A (en) | 1993-05-01 |
NZ245167A (en) | 1995-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU644016B2 (en) | Phenylpyridinol derivatives as medicaments | |
JP5000683B2 (en) | Substituted phenylalkanoic acid derivatives and uses thereof | |
US4752613A (en) | Sulphonamidothienylcarboxylic acid compounds | |
AU642743B2 (en) | Phenol and pyridinol derivatives as pharmaceuticals | |
CZ373096A3 (en) | Trisubstituted phenyl derivatives, process of their preparation and pharmaceutical compositions containing thereof | |
GB2025973A (en) | Indanyl derivatives and pharmaceutical preparations containing them | |
NO173012B (en) | ANALOGY PROCEDURE FOR MANUFACTURING ANTI-INFLAMMATORY FURANONES | |
WO1993010114A1 (en) | 3-pyridinol derivatives and their use as medicaments | |
JP3300369B2 (en) | Process for producing 2-aryl-3-aryl-5-halopyridines useful as COX-2 inhibitors | |
AU654051B2 (en) | Pyridinol derivatives as medicaments | |
AU2927492A (en) | Phenol derivatives as agonists of a cyclic amp dependent protein kinase | |
WO1993010093A1 (en) | 2-pyridinol derivatives and their use as medicaments | |
US4812584A (en) | Aralkoxy and aryloxyalkoxy kojic acid derivatives | |
US4705871A (en) | Aralkoxy and aryloxyalkoxy kojic acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992923524 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1994 244074 Country of ref document: US Date of ref document: 19940517 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2124002 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1992923524 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992923524 Country of ref document: EP |